

Global Health Innovation Act (H.R. 2241)

A bill to advance US leadership in global health innovation

WHAT THE BILL WILL DO:

The Global Health Innovation Act will encourage the development of new health technologies that are key to advancing global health around the world by supporting the development, advancement, introduction, and scale-up of health innovations at the US Agency for International Development (USAID).

The legislation will:

- **Formalize USAID's annual report to Congress on health-related research and development (R&D) activities**
The report will provide a comprehensive analysis of USAID's activities to develop, advance, introduce, and scale-up global health technologies.
- **Provide transparency into USAID decision-making and progress in health R&D**
USAID must describe how it sets goals for health R&D in relation to its overall health objectives and mission, and how the agency measures progress towards these goals.
- **Demonstrate the impact of USAID investment in health innovations on global health outcomes**
USAID will report on how its activities in health innovation have advanced goals to reduce the burden of HIV/AIDS, end preventable child and maternal deaths, and protect against infectious diseases, among other global health objectives.
- **Incentivize innovative partnerships for global health technologies**
USAID will quantify its work with partners, donors, and public-private partnerships to leverage US investments, accelerate health innovation, and close gaps in the product development pipeline.
- **Leverage existing resources and encourage government-wide coordination in global health R&D**
H.R. 2241 will require no new funding. The bill leverages resources by promoting collaboration and information-sharing within USAID and requiring a whole-of-government strategy for global health research that coordinates the funding, monitoring, and strategy of the many agencies involved in health R&D.

WHY THIS BILL MATTERS:

- New vaccines, drugs, diagnostics, and other health tools are desperately needed to combat systemic and emerging health challenges that claim the lives of nearly 9 million people each year. Progress in addressing these challenges cannot be made without a sustained investment in R&D.
- Global health R&D is a smart economic investment, creating jobs and driving business activity in the United States. 64 cents of every US dollar invested in global health research goes directly to US-based researchers.
- The United States' leadership in global health R&D has produced several technologies that are already having an impact—such as the vaccine vial monitor and the GeneXpert TB diagnostic. H.R. 2241 will help sustain this leadership and ensure critical technologies in the research pipeline are able to contribute to progress in global public health.
- USAID's R&D programs work through public private partnerships—an effective way of combining the resources of government, the private sector, and the know-how of NGOs.